Mobia Medical Sets Terms for $150M IPO

Why It Matters

The IPO provides critical funding to scale sales and address reimbursement hurdles, positioning Mobia to capture a niche yet expanding neurostimulation market. Investors will gauge whether the capital infusion can turn a loss‑making startup into a sustainable revenue generator.

Key Takeaways

• Mobia aims to raise up to $155 million in IPO
• Vivistim targets chronic ischemic stroke survivors with severe impairments
• IPO proceeds will fund $93.5 million sales force expansion
• CMS reimbursement uncertainty may delay revenue growth
• Company posted $46.5 million net loss, raising going‑concern doubts

Pulse Analysis

The neurostimulation sector is experiencing a wave of capital inflows as investors chase innovative therapies that address unmet neurological needs. Mobia Medical’s IPO arrives at a time when larger players like Medtronic and Boston Scientific are expanding their portfolios, creating a competitive yet collaborative ecosystem. By positioning its Vivistim System as the sole FDA‑cleared solution for chronic ischemic stroke with upper‑extremity deficits, Mobia differentiates itself, but the market’s appetite hinges on demonstrated clinical outcomes and scalable commercial execution.

Vivistim’s paired vagus‑nerve stimulation technology leverages neuromodulation to enhance neuroplasticity during task‑specific rehabilitation. Early adoption data show over 1,000 implants, with 700 placed in 2025 alone, suggesting clinician confidence. However, the device’s commercial trajectory is complicated by the expiration of CMS transitional pass‑through payments and a shift to a new ambulatory payment classification that may take two to three years to generate reliable claim data. Payers continue to label the therapy experimental, imposing prior‑authorization hurdles that could slow adoption and strain cash flow.

Financially, Mobia reported a $46.5 million net loss for 2025 and carries $55.7 million in cash, underscoring the urgency of the capital raise. The IPO’s proceeds are earmarked for a $93.5 million expansion of the sales force, aiming to broaden geographic coverage and accelerate market penetration. While the infusion should sustain operations for at least a year, investors must weigh the risk of continued reimbursement uncertainty against the upside of capturing a high‑margin, niche market. Success will depend on securing stable payer pathways and translating clinical promise into consistent revenue streams, a challenge that will define the next phase of growth for Mobia and the broader neurostimulation landscape.

Deal Summary

Mobia Medical, a neurostimulation-device maker, announced it will raise about $150 million in an initial public offering, offering 10 million shares at $14‑$16 each and expecting net proceeds of $134.5 million (up to $155.4 million with the underwriters’ option). The proceeds will fund expansion of its direct sales force and commercial organization. The filing was disclosed on May 5, 2026.